SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Merrill Peter D.)
 

Search: WFRF:(Merrill Peter D.) > Premature permanent...

  • Carnicelli, Anthony P.Duke Clin Res Inst, Durham, NC 27701 USA. (author)

Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2020-09-16
  • BMJ Publishing Group Ltd,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-443091
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-443091URI
  • https://doi.org/10.1136/heartjnl-2020-317229DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Aims The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who prematurely permanently discontinued study drug.Methods/Results We performed a posthoc analysis of patients from ARISTOTLE who prematurely permanently discontinued study drug during the study or follow-up period. Discontinuation rates and reasons for discontinuation were described. Death, thromboembolism (stroke, transient ischaemic attack, systemic embolism), myocardial infarction and major bleeding rates were stratified by <= 30 days or >30 days after discontinuation. A total of 4063/18 140 (22.4%) patients discontinued study drug at a median of 7.3 (2.2, 15.2) months after randomisation. Patients with discontinuation were more likely to be female and had a higher prevalence of cardiovascular disease, diabetes, renal impairment and anaemia. Premature permanent discontinuation was more common in those randomised to warfarin than apixaban (23.4% vs 21.4%; p=0.002). The most common reasons for discontinuation were patient request (46.1%) and adverse event (34.9%), with no significant difference between treatment groups. The cumulative incidence of clinical events <= 30 days after premature permanent discontinuation for all-cause death, thromboembolism, myocardial infarction, and major bleeding was 5.8%, 2.6%, 0.9%, and 3.0%, respectively. No significant difference was seen between treatment groups with respect to clinical outcomes after discontinuation.Conclusion Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Al-Khatib, Sana M.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Xavier, DenisSt Johns Med Coll, Bangalore, Karnataka, India. (author)
  • Dalgaard, FrederikGentofte Univ Hosp, Cardiol, Hellerup, Hovedstaden, Denmark. (author)
  • Merrill, Peter D.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Wojdyla, Daniel M.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Lewis, Basil S.Lady Davies Carmel Med Ctr, Haifa, Israel. (author)
  • Hanna, MichaelBristol Myers Squibb Pharmaceut Res & Dev, Princeton, NJ USA. (author)
  • Alexander, John H.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Lopes, Renato D.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Wallentin, Lars,1943-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (author)
  • Granger, Christopher B.Duke Clin Res Inst, Durham, NC 27701 USA. (author)
  • Duke Clin Res Inst, Durham, NC 27701 USA.St Johns Med Coll, Bangalore, Karnataka, India. (creator_code:org_t)

Related titles

  • In:Heart: BMJ Publishing Group Ltd107:9, s. 713-7201355-60371468-201X

Internet link

Find in a library

  • Heart (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view